Amedisys Inc (NASDAQ:AMED) Position Reduced by California State Teachers Retirement System

California State Teachers Retirement System lessened its holdings in Amedisys Inc (NASDAQ:AMED) by 2.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 40,944 shares of the health services provider’s stock after selling 1,057 shares during the quarter. California State Teachers Retirement System’s holdings in Amedisys were worth $5,047,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Alpha Quant Advisors LLC grew its holdings in shares of Amedisys by 137.0% during the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after purchasing an additional 137 shares during the last quarter. Financial Gravity Companies Inc. purchased a new position in shares of Amedisys during the fourth quarter worth about $50,000. Captrust Financial Advisors grew its holdings in shares of Amedisys by 161.8% during the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after purchasing an additional 369 shares during the last quarter. Group One Trading L.P. purchased a new position in shares of Amedisys during the fourth quarter worth about $90,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Amedisys by 102.3% during the first quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock worth $120,000 after purchasing an additional 488 shares during the last quarter. 86.30% of the stock is currently owned by hedge funds and other institutional investors.

AMED stock opened at $118.04 on Thursday. Amedisys Inc has a 12-month low of $80.13 and a 12-month high of $140.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91. The company has a market cap of $3.77 billion, a PE ratio of 29.62, a P/E/G ratio of 1.46 and a beta of 1.40.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company had revenue of $467.34 million during the quarter, compared to the consensus estimate of $460.83 million. During the same period last year, the firm earned $0.79 EPS. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, analysts forecast that Amedisys Inc will post 4.08 earnings per share for the current year.

In other news, insider Michael Paul North sold 5,248 shares of Amedisys stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $115.01, for a total transaction of $603,572.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott G. Ginn sold 4,872 shares of Amedisys stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $118.50, for a total transaction of $577,332.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,165 shares of company stock valued at $4,990,556. Insiders own 2.90% of the company’s stock.

Several equities analysts have issued reports on the company. BidaskClub lowered Amedisys from a “hold” rating to a “sell” rating in a report on Friday, May 17th. ValuEngine downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Craig Hallum reduced their price objective on shares of Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a research report on Friday, March 1st. They noted that the move was a valuation call. Raymond James upgraded shares of Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price objective for the company in a research report on Thursday, May 2nd. Finally, Barclays raised their price objective on shares of Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, March 21st. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $129.89.

TRADEMARK VIOLATION WARNING: “Amedisys Inc (NASDAQ:AMED) Position Reduced by California State Teachers Retirement System” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2019/06/13/amedisys-inc-nasdaqamed-position-reduced-by-california-state-teachers-retirement-system.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: How to Use a Moving Average for Trading 

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.